cgem: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net cash provided by financing activities	373	373
Net increase in cash and cash equivalents	20,330	-10,185
Cash and cash equivalents at beginning of period	83,005	-
Cash and cash equivalents at end of period	103,335	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net cash provided by financing activities	373	373
Net increase in cash and cash equivalents	20,330	-10,185
Cash and cash equivalents at beginning of period	83,005	-
Cash and cash equivalents at end of period	103,335	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cullinan Therapeutics, Inc. (CGEM)